*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
GTX14613 labels all PDE4D proteins including PDE4D1, PDE4D2, PDE4D3, PDE4D4, PDE4D5 variants. Does not cross react with PDE4A, PDE4B or PDE4C.
Preservative: 0.02% Thimerosal / Merthiolate
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.5 mg/ml (Please refer to the vial label for the specific concentration.)
C-terminal cyclic peptide unique to all PDE4D subtypes variants.
Immunogen affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Cyclic AMP-dependent phosphodiesterase type D (PDE4D) family is comprise of 5 variants (PDE4D1, D2, D3, D4 and D5). One or more PDE4D subtype-variants are ubiquitously present in all mammalian cells. In CNS all five PDE4D subtype-variants are expressed in varying ratios and their activity is regulated in tandem with GPCRs stimulation. Peripheral tissues also exhibit differential expression of PDE4D variants. PDE4D1/D2 mRNA levels rise in response to an increase in cAMP. Short-term regulation of PDE4D variants involved PKA, MAP kinases and Erk2 phosphorylation that results in rapid change in their enzymatic activities. Other regulatory mechanism involved protein-protein interactions with cytoskeletal scaffolding proteins.